skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction

Review

(3129) Views  (576) Full article downloads

Authors: William H Frishman, Linda S Henderson, Mary Ann Lukas

Published Date December 2008 Volume 2008:4(6) Pages 1387 - 1400
DOI: http://dx.doi.org/10.2147/VHRM.S3148

William H Frishman1, Linda S Henderson2, Mary Ann Lukas2

1Departments of Medicine and Pharmacology, New York Medical College/Westchester Medical Center, Valhalla, NY, USA; 2Cardiovascular and Metabolic Medicine Development Center, GlaxoSmithKline, Philadelphia, PA, USA

Abstract: Cardiovascular disease is the leading cause of death worldwide. Within the treatment armamentarium, beta-blockers have demonstrated efficacy across the spectrum of cardiovascular disease – from modification of a risk factor (ie, hypertension) to treatment after an acute event (ie, myocardial infarction). Recently, the use of beta-blockers as a first-line therapy in hypertension has been called into question. Moreover, beta-blockers as a class are saddled with a misperception of having poor tolerability. However, vasodilatory beta-blockers such as carvedilol have a different hemodynamic action that provides the benefits of beta-blockade with the addition of vasodilation resulting from alpha 1-adrenergic receptor blockade. Vasodilation reduces total peripheral resistance, which may produce an overall positive effect on tolerability. Recently, a new, controlled-release carvedilol formulation has been developed that provides the clinical efficacy of carvedilol but is indicated for once-daily dosing. This review presents an overview of the clinical and pharmacologic carvedilol controlled-release data.

Keywords: beta-blockers, cardiovascular disease, heart failure, myocardial infarction, vasodilatory








Readers of this article also read:

Carvedilol in hypertension treatment
Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension
Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
Coronary computed tomographic angiography (CCTA) in community hospitals: “current and emerging role”
Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits
Corrigendum
Current state of cardiac rehabilitation in Germany: patient characteristics, risk factor management and control status, by education level
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University